Skip to main content
. 2017 Feb 9;18(2):363. doi: 10.3390/ijms18020363
CA15-3 Cancer Antigen 15-3
CTC Circulating Tumor Cell
DEAC Development, Evaluation and Application Chart
PFS Progression Free Survival
HER2 Human Epidermal Growth Factor Receptor 2
OS Overall Survival
VEGF Vascular Endothelial Growth Factor
VEGFR Vascular Endothelial Growth Factor Receptor